Reaction

Haemolytic Uraemic Syndrome reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,315 reports · 74 co-occurring drugs

As of the last recalculation, Haemolytic Uraemic Syndrome appears in 2,315 FAERS reports alongside 74 co-occurring drug terms. The strongest observed disproportionality signal is BASILIXIMAB (PRR 54.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Basiliximab	69	54.3	54.7
Anti-Thymocyte Globulin (Rabbit)	45	51.1	51.4
Gemcitabine	185	45.8	46.0
Gemcitabine Hydrochloride	239	45.0	45.2
Eculizumab	201	36.3	36.5
Carfilzomib	96	31.8	31.9
Valganciclovir Hydrochloride Powder,	36	26.9	27.0
Tacrolimus	346	23.2	23.2
Tacrolimus Ointment 0.1%	283	23.1	23.2
Tacrolimus Extended-Release Capsules	283	23.1	23.1
Valganciclovir	47	22.9	22.9
Valganciclovir Hydrochloride	47	22.9	22.9
Everolimus Tablets	40	21.8	21.9
Mycophenolate Mofetil Hydrochloride	250	18.4	18.4
Mycophenolate Mofetil	249	18.3	18.4
Ganciclovir Sodium	18	15.4	15.4
Ganciclovir	17	15.0	15.1
Sirolimus	21	14.1	14.2
Mycophenolic Acid	47	13.5	13.5
Mycophenilic Acid	28	12.3	12.3
Mercaptopurine	23	12.0	12.0
Cyclosporine	137	11.7	11.7
Melphalan Hydrochloride	32	11.6	11.6
Melphalan	29	11.6	11.6
Thiotepa	12	11.4	11.4
Bleomycin Sulfate	12	10.5	10.5
Ampicillin	9	9.8	9.8
Ampicillin Sodium	9	9.8	9.8
Vincristine Sulfate	31	9.6	9.6
Metronidazole Topical	46	8.8	8.8
Acetylcysteine	9	8.6	8.6
Itraconazole	11	8.5	8.5
Quinine	8	8.4	8.4
Gentamicin	12	8.3	8.3
Gentamicin Sulfate	14	8.0	8.0
Prednisolone	151	8.0	8.0
Prednisolone Oral	151	8.0	8.0
Prednisolone Oral Solution	151	8.0	8.0
Mesna Injection	7	7.6	7.6
Everolimus	42	7.5	7.5
Mesna	7	7.5	7.5
Metronidazole	52	7.5	7.5
Micafungin Sodium	7	7.4	7.4
Leucovorin Calcium	15	7.1	7.1
Labetalol	10	6.8	6.8
Atovaquone	6	6.7	6.7
Paclitaxel	71	6.6	6.6
Fluorouracil Cream, 0.5%	55	6.6	6.6
Fluorouracil	55	6.5	6.5
Clarithromycin	23	6.1	6.1
Cetuximab	21	6.1	6.1
Filgrastim	25	6.0	6.0
Cisplatin	51	6.0	6.0
Oxaliplatin	48	5.9	5.9
Paclitaxel (Aibumin-Bound)	46	5.1	5.1
Fludarabine Phosphate	22	5.1	5.1
Posaconazole	9	5.0	5.0
Bevacizumab	66	4.9	4.9
Carboplatin	67	4.9	4.9
Pancrelipase	20	4.7	4.7
Ravulizumab	7	4.7	4.7
Rocuronium Bromide	6	4.6	4.6
Cyclophosphamide Injection, Solution	86	4.5	4.5
Cyclophosphamide	86	4.5	4.5
Cyclophosphamide For Injection	86	4.5	4.5
Docetaxel Anhydrous	33	4.5	4.5
Docetaxel	33	4.5	4.5
Sunitinib Malate	19	4.4	4.4
Bendamustine Hcl	7	4.1	4.1
Durvalumab	8	3.5	3.5
Irinotecan Hydrochloride	5	3.5	3.5
Pazopanib Hydrochloride	9	3.0	3.0
Dornase Alfa	6	2.8	2.8
Minoxidil Foam 5% (Womens)	5	1.4	1.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.